This article is more than 5 years old. Information may no longer be current.

Alcon's annual operating income falls 16%

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Operating income for Alcon in 2013 was $1.2 billion, a decline of 16% over the previous year, according to a press release from Novartis.

The decline was attributed to integration and restructuring costs and was partially offset by sales growth — 3% over the previous year — and productivity gains.

The Alcon surgical franchise increased by 4% in 2013 over 2012. This was driven by procedure growth, market share gains and demand for LenSx and Centurion equipment.

Ophthalmic pharmaceuticals grew 2% in 2013 due to market share gains across key segments, but generic competition affected the U.S. glaucoma segment.

Vision care experienced 2% growth.

Novartis reported a net income of $9.29 billion for 2013, representing a 1% decline over 2012.

Net income for the fourth quarter was $2.06 billion, a 2% increase over $2.02 billion reported in the fourth quarter of 2012.